18 September 2024FeaturesUnified Patent CourtJan Phillip Rektorsche, Matthew Royle
Takeaways from landmark UPC decision: Novartis v Celltrion
A recent UPC ruling involving Novartis has major implications for determining jurisdiction, claim interpretation and imminent infringement, as Jan Phillip Rektorschek and Matthew Royle of Taylor Wessing explain.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
17 September 2024 The court rejected the medical device company’s auxiliary requests and nixed patent in 17 territories although it seems receptive to these amendments in general, say Laura Orlando and Rachel Montagnon of Herbert Smith Freehills
2 September 2024 A vocal advocate of greater UPC transparency, Freshfields’ Christopher Stothers shares his views on the court’s journey so far, and why it is still so exciting.
23 July 2025 Important cases on discretionary denials, prosecution laches, and trade secrets have been heard at the appellate court over June and July, explain Nathan Mammen and Cole Tipton of Snell & Wilmer.